UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2020

HILLENBRAND, INC.

(Exact Name of Registrant as Specified in Charter) 1-33794

Indiana (State of Incorporation)

(Commission File Number)

26-1342272 (IRS Employer Identification No.)

One Batesville Boulevard

Batesville, Indiana

(Address of Principal Executive Office)

Registrant's telephone number, including area code: (812) 934-7500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Derecommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, without par value	HI	New York Stock Exchange

Indicate by the check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

47006 (Zip Code)

Item 7.01. Regulation FD Disclosure.

Beginning on June 2, 2020, Hillenbrand, Inc. ("Hillenbrand") intends to meet from time to time and make presentations to current and prospective investors. Exhibit 99.1 provides a copy of the slides that may be used in connection with or referenced in such meetings.

This Current Report on Form 8-K and the documents included as exhibits hereto are for informational purposes only and shall not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities.

Exhibit 99.1 is incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any Hillenbrand filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description of Exhibit
<u>99.1</u>	Current and Prospective Investor Meeting Slides
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 1, 2020

HILLENBRAND, INC.

By: <u>/s/ Nicholas R. Farrell</u> Name: Nicholas R. Farrell Title: Vice President, General Counsel, Secretary, and Chief Compliance Officer



Hillenbrand



Joe Raver President & Chief Executive Officer



Kristina Cerniglia Senior Vice President & Chief Financial Officer



performance

Throughout this presentation, we make a number of "forward-looking statements" within the meaning of Section 27A of the Securities Actof 1944, as amended (the "Securities Act"). Section 21E of the Securities Exchange Act of 1924, as amended and the Private Securities Ligation Reform Actof 1966 and that are intended to be covered by the safe harbor provided under these sections. As the words imply, these are statements about future sales, earnings, cash flow, results of operations, uses of cash, financings, share nucricases, ability to meet delevering goals, and other measures of financial performance or potential future plans or events, strategies, objectives, belefs, prospects, assumptions, expectations and projected costs or savings or transactions of the Company' that might or might not happen in the future, as contrasted with historical information. Forward-looking statements are based on assumptions that we believe are reasonable, but by their very nature are subject to a widerange of risks. If our assumptions prove inaccurate or unknown risks and uncertainties materialize, actual results could vary materially from Hilenbrand's (the "Company") expectations and projections.

Words that could indicate that we are making forward-looking statements include the following and similar expressions in connection with any discussion of the timing or nature of future operating or financial

intend	believe	plan	expect	may	goal	would	project
become	pursue	estimate	wit	forecast	continue	could	anticipate
target	impact	promise	improve	progress	potential	should	encourage

This is not an exhaustive list but is intended to give you an idea of how we try to identify forward-booking statements. The absence of any of these words, how ever, does not mean that the statement is not forward-looking.

Here is the key point: Forward-looking statements are not guarantees of future performance to differ significantly from whats described in the forward-looking statements. These factors include, but are not limited to: the impact of contagois and/looking statements are not guarantees of future performance to differ significantly from whats described in the forward-looking statements. These factors include, but are not limited to: the impact of contagois and/looking statements, and which are beyond our control, could cause our performance to differ significantly from whats described in the forward-looking statements. These factors include, but are not limited to: the impact of contagois and/looking statements, including supply chain disruptions, loss of human capital or personnel, and general economic catalmites that in any torward-looking statements and economic control coustomers; and contracts including potential synergies and costsavings or supplyers immutacturing facilities, travel, shipping and bgistical disruptions, loss of human capital or personnel, and general economic catalmites in the integration of Miacron or any other integration, acquisition or disposition activity disrupts current operations, subtativity devices familiate or personnel, subtativity of curitors personnels, which are explicitly on any companies we may acquired company to achieve its plans and objectives generality; global market and economic conditions, including those related to alary logal proceedings related to operations, subtadentes in the the Company is nonection in the acquisition of Miacron or any other intension of any logal proceedings related to comply with this and juridictors; labor diary logal proceedings related to persons), control and plags proceedings related to any logal proceedings related to persons, subtential or the company is an ence to ence the intension of the company to any acquired organization, or classes down and and plags proceedings related to personsels controls and juridictors; labor diary logal proc

Market and Industry Data

This presentation also includes market and industry data that the Company has obtained from market research, publicly available information and industry publications. The accuracy and completeness of such information are not guaranteed. Such data is often based on industry surveys and preparers' experience in the industry. Similarly, although the Company believes that the surveys and market research that others have performed are reliable, such surveys and market research are subject to assumptions, estimates and other uncertainties and the Company has not independently verified this information.

No Offer or Solicitation

This presentation is confidential and is for your information only and is not intended to be used by anyone other than you. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or pursuant to another available exemption.

Non-GAAP Financial Measures

This presentation contains certain supplemental non-GAAP financial measures. While the Company believes that non-GAAP financial measures are helpful in evaluating its operating performance, the use of non-GAAP financial measures in this presentation should not be considered in isolation from, or as an alternative for, a measure of financial or operating performance as defined by GAAP. You are cautioned that there are inherent limitations associated with the use of each of these supplemental non-GAAP financial measures as an analytical tool. Additionally, the Company's company's company's company for the supplemental non-GAAP financial measures as an analytical tool. Additionally, the Company's company's company is and the support of the support of the non GAAP financial measures used in this presentation to the most directly comparable GAAP financial measures, to the extent available without unreasonable efforts, in this presentation.

Pro Form a Financial Measures

This presentation contains certain financial results that reflect Milacron's results of operations in a number of scenarios. Actual results include Milacron from the date the acquisition closed on November 21, 2019. Po forma results give effect to the acquisition as if it had been completed as of the earliest date of the period reported. The Company's Cimcool business ("Cimcool"), which represented approximately 4% of Hilenbrand's adjusted EBITDA for the quarter ended March 31, 2020, is not included. On March 30, 2020, the Company completed the sale of Cimcool. In certain instances, including slides 22 and 38, of this presentation, Milacron pro forma results are presented for periods ended December 31, for 2018 and 2017 fiscal year-end, while Milacron pro forma results are presented for the period ended September 30, for 2019 fiscal year-end. As a result, in these instances the Milacron results for the fourth quarter of 2018 are reflected in both the 2018 and 2019 fiscal year-end financial results.

In calculating the pro forma figures included in this presentation, the Company completed calculations generally consistent with the pro forma presentation previously incorporated by reference into their Current Report on Form 8-K filed on November 21, 2019.

1Key Takeaways62Hillenbrand Overview & Strategy83- Process Equipment Group124- Milacron165- Batesville256COVID-19 Update297Financial Policy and Performance34	Age	enda		Hillenbrand
3- Process Equipment Group124- Milacron165- Batesville256COVID-19 Update297Financial Policy and Performance34	1	Key Takeaways	6	A L
4- Milacron165- Batesville256COVID-19 Update297Financial Policy and Performance34	2	Hillenbrand Overview & Strategy	8	
5- Batesville256COVID-19 Update297Financial Policy and Performance34	3	- Process Equipment Group	12	-
6COVID-19 Update297Financial Policy and Performance34	4	- Milacron	16	Chan 42
7 Financial Policy and Performance 34	5	- Batesville	25	
	6	COVID-19 Update	29	
	7	Financial Policy and Performance	34	AL PROPERTY
8 Capitalization Overview 43	8	Capitalization Overview	43	at the state
9 Key Takeaways & Closing Remarks 45	9	Key Takeaways & Closing Remarks	45	
10 Appendix 47	10	Appendix	47	



Key Takeaways

01	02	03	04	05	06
Significant Strides	Market Leadership	The Hillenbrand	Focused on Building	Strong Free Cash	Passionate
Transforming	Driven by Highly-	Operating Model	Platforms to	Flow With Focus	Leadership Team
Hillenbrand into a	Engineered	(HOM) is a	Develop Scale and	on Paying Down	Driving
Global Diversified	Products with Core	Competitive	Enhance	Debt Post-Milacron	Transformation with
Industrial	Technologies	Differentiator;	Leadership	Acquisition;	Runway for
Company	Differentiated by	Historically Focused	Positions to Drive	Temporarily	Significant
	Applications	on Margin	Profitable Growth;	Lowering Priority of	Shareholder Value
	Expertise	Expansion and Now	Integrating Milacron	M&A and Share	Creation
		Adding Tools to	is a Key Priority	Repurchases	
		Drive Profitable			
		Growth			
	A HOLE				






HILLENBRAND OVERVIEW & STRATEGY

Hillenbrand Snapshot¹ (NYSE: HI)

Global Diversified Industrial Company that Engineers, Manufactures, and Sells Products and Services into a Variety of End Markets



	Dive	rsified End Marke	ts ⁴			
Plastics 29%	Death Care 19%	Custom Molders 10%	Automotive 7%	Consumer Goods 5% Packaging 4%	Minerals/ Mining 3% Construction 3%	Other 14%

¹ All financial metrics exclude the diverted Crimocol and Blow Molding businesses, which were sold in March 2020 and July 2019, respectively. ¹As of 4115/2020. ³ Indudes headquarters, significant manufacturing and sales & technical locations. ⁴ Represents total of previously disclosed Hillenbrand financial data for FYE 9/30/2019 and Milacronfinancial data conformed to Hillenbrands FYE 9/30/2019. ⁵ Pro Forma adjusted EBITDA marginis a non-GAAP measure. See appendix for GAAP recordination. ⁴ Based on customer location. INVESTOR PRESENTATION 9

Adapting Our Strategy for the Current Environment



HIGHLIGHTS

- ✓ Focus in niche markets, specifically plastics and chemicals, food and pharma, and separation
- ✓ Expanded product offering via acquisition of Milacron
- ✓ In the 2015 / 2016 Industrial Recession, PEG margin expanded ~250 basis points1

Seasoned Management Team Balancing Near-term Priorities with Unwavering Focus on Long-term

¹ Represents Adjusted EBITDA margin expansion from FY 2014 – FY 2016.



STRATEGY

GROW

VALUES

igger and Bette

STAND

Ger

10/551W

Consistent and Repeatable Framework Designed to Produce Efficient Processes and Drive Profitable Growth and Superior Value


UNDERSTAND THE BUSINESS



GROW: GET BIGGER AND BETTER


Have Realized Benefits but Significant Opportunity Ahead of Us





PROCESS EQUIPMENT GROUP

Process Equipment Group at a Glance



Hillenbrand Operating Model Drives Strong Profit Margin and Free Cash Flow

¹ Based on FY 2019 sales.² Based on customer location.³ Adjusted EBITDA Margin is a non-GAAP measure. See appendix for GAAP reconsiliation. ⁴See appendix for discussion of calculation of backlog.

Diverse Brands with Significant Scale in Plastics

	coperion	ROTEX	Pump Technology Red Valve	TERRASOURCE
PRODUCT PORTFOLIO	Products: Compounders and extruders Material handling equipment Feeders, components, and system solutions Parts & service	Separation Products: • Screening equipment • Sizing equipment • Parts & service	Flow Control Products: • Pumping solutions • Highly-engineered valves • Parts & service	Size Reduction Products: • Crushers • Material handling equipment • Parts & service
END MARKETS	 Polyolefins Engineered Plastics Chemicals Processed Food & Pharma 	Minerals & Fertilizers Food & Agriculture Proppants	Municipal Water and Wastewater Industrial Water and Wastewater	Coal Power & Mining Forest Products Steel
Portion of Peg Revenue				
SELECT PEG CUSTOMERS	Good Jun!	E)		
¹ Based on FY 2019 sales.				INVESTOR PRESENTATION

Strengthen Leadership Positions and Build Targeted Platforms


- · Leverage core technologies and applications expertise to further penetrate current markets
- Grow platforms to critical mass in plastics & chemicals, food & pharma, and separation, to achieve benefits of market leadership and scale
- . Enter attractive new markets and near adjacencies with large addressable opportunities
- · Leverage global footprint to expand customer base and obtain leadership positions in new markets

Drive Innovation and New Product Development

- Provide innovative product and service solutions to solve customers' challenges
- · Extend applications expertise to obtain leadership positions in adjacent markets with high growth potential
- Develop new products driven by voice of customer input and changing needs
- · Provide value-added end-to-end solutions from individual components to integrated systems

Leverage HOM to Drive Margin Expansion and Profitable Growth

- Apply HOM tools, including voice of customer and segmentation, for profitable growth
- · Drive best-in-class lead times to grow share in aftermarket parts & service business
- · Activate strategic supplier relationships to improve cost and quality
- · Enhance productivity through process standardization



Transaction Overview	Milacron Seg	ment Overview ¹
Transaction closed November 21, 2019	\$940M FY'19 PF Revenue ~ 19.4%	\$182M FY19 PF Adj. EBITDA ² ~5,000
 Terms Deal valued at ~\$1.9B, including repayment of Miacron's outstanding debt Milacron stockholders received \$11.80 in cash and 0.1612 Hillenbrand shares per Milacron share Milacron stockholders owned ~16% of Hillenbrand's outstanding shares on an immediately post-close basis 	FY'19 PF Adj. EBITDA Margin ² Leader in manufacturing, distribution a customized plastic and fluid technolog Strong market positions and industry- <u>Melt Delivery & Control System</u> in Americas, #1 in Europe, #2 i Advanced Plastics Processing	ies and processing systems eading brands <u>is:</u> #2 in premium hot runners globally (#1 n Asia)
 Financial Details Targeting to achieve annualized, run-rate cost synergies of ~\$50M within three years³ Targeting ~\$20-25M of cost synergies within the first 12 months post-closing³ Completed the sale of the Cimcool business (legacy Fluids Technologies segment of Mlacron) on March 30, 2020 in a transaction valued at ~\$224M 	Equipment: Full line supp (#1 in North America, #1 Aftermarket: Top global s <u>Fluids Technologies</u> : Global ma metalworking processes	lier of injection and extrusion equipment in India) upplier to installed machine base

HILLENBRAND



A Transformative Deal to Create Meaningful Shareholder Value

Macro Trends Support Long-Term Sustained Growth for Durable Plastics

design flexibility

Secular Trends ✓ Medical applications focus on safety, improved drug and ~ Demand for products driven by strong secular trends, including a growing middle class therapy delivery, as well as durability ✓ Automotive increased use of lightweight plastics to Construction ongoing shift to plastics that are more durable, improve fuel efficiency lightweight and require little maintenance ✓ Packaging in emerging markets to improve food shelf life, ~ Increased desire for eco-friendly innovations in the use of freshness, and safety plastics and base materials **Diverse, Long-Term Drivers** Ň Electronics **Consumer Goods** Packaging **Eco-friendly** Medical Automotive Construction Bio Resin and recycled Superior quality, shorter Shortened product Vehicle light-weighting Increased freshness, Shift to plastics for product lifecycles, and lifecycles, innovation in extended shelf life, and durability, light weight materials design flexibility multi-material products, product visibility and low maintenance

Milacron Strengthens Position Across Plastics Value Chain




Stronger Position Across the Plastics Value Chain to Capitalize on New Opportunities

Significant Catalysts and Opportunities of the Combined Company



Milacron at a Glance¹



Milacron Strengthens Hillenbrand's Position Across The Plastics Value Chain

¹ All figures exclude the diverted Cimcool and Blow Molding businesses, which were sold in March 2020 and July 2019, respectively.² Based on Mlacron financial data for the twelve months ended September 30, 2018. ³ Based on customer location. ⁴ FY 18 and FY 17 includes Milacron results for the twelve months ended September 30, 2018 and 2017, respectively, while FY 10 includes Milacron results for the twelve months ended September 30, 2018 and 2017, respectively, while FY 10 includes Milacron results for the twelve months ended September 30, 2018. As a result, the Milacron results for the twelve months ended September 30, 2018 and 2019 fincal year-end financial results. ⁵ Pro Form Adjusted EBITON Amplitude EBITON Amplitude Kord AP Concollision. ⁵ Evel approxils for discussion of the calution of backtog.

HILLENBRAND

Strong Brands in Plastics Processing Technologies

BRANDS	Mold Masters performance delivered	MILACRON Every step o		Read FER	ROMATI
PRODUCT PORTFOLIO					See.
	Hot runner syste	ems and mold bases	Extrusion	Injection molding	Parts & service
END MARKETS	Construction	Consumer Goods	Medical	Custo	m Molding
	Automotive	Packaging	Electronics	Cusio	minolaing
SELECT	corvaglia Rutter	. FOXCONN' SAMSUN	G 3M 🎒	Johmon-Johmon L'	OREAL Whirlpool
MILACRON	🖌 IBERRU 💭	NYPRO	+ fitbit -	BOSE KEUR	IG Colgate
CUSTOMERS	TATTET OMEG	Uniferent Johen Di			RED.
		NDA P&G 👫 Microso	oft 👿 DE	LPHI dyson	BOSCH TOYOTA

Making Solid Progress on Integrating Milacron

Key Milestones Achieved this Quarter

- Integration proceeding as planned, despite unexpected challenges associated with COVID-19
- Completed sale of Cimcool business in a transaction valued at ~\$224M on March 30, 2020
- Initiated restructuring activities resulting in a facility closure and reduction in fixed costs
- Achieved \$6M of cost synergies in Q2'20 primarily driven by reduction of duplicate public company cost

Identifying and Capturing Strategic Benefits

- Strong product and technology positions across plastics value chain; revenue synergy opportunities across portfolio
- Enhancing position in new/current markets with broader offering sharing R&D and technology to serve evolving needs (e.g., recycling)
- Achieving supply chain and operating efficiencies through leveraging our global footprint and spend
- Building a scalable back office: working capital / global functions / business services
- Leveraging HOM playbook to drive margins, especially in injection molding and extrusion product lines (formerly APPT)

\$50M

Expected Run-rate Cost Synergies within 3 Years Post-close


\$20-25M

- Reducing public company costs
- Realizing operating efficiencies
- Capturing (in) direct spend opportunities

 On track to realize synergies within fiscal 2020

Year 1 Target





Leadership Drives Strong Profit Margins and Free Cash Flow

Adjusted EBITDA Margin is a non-GAAP measure. See appendix for GAAP recorciliation.

Sizable Market Impacted by Changing Consumer Preferences



· Demand for caskets driven by long-term, predictable demographics, and consumer trends

· Consumer spending on caskets has not kept pace with inflation, resulting in annual mix decline

· Addressing industry challenges using HOM to guide our investments in new products and solutions

Source: CDC, Cremation Association of North America, NFDA, and Company estimates.

Grow Leadership Position in Death Care

- . Leverage HOM to deliver value propositions that align with the needs of unique customer segments
- · Introduce new products and solutions in response to consumer trends
- · Create personalization options aligned with consumer preferences
- · Leverage technology to enhance consumer experience and create efficiencies for our customers

Optimize Business Structure to Drive Profitability and Cash Flow

- Drive supply chain and SG&A productivity through continued application of HOM
- · Continually improve processes to be more consistent and efficient and to yield industry leading quality products and services that our customers value
- Enhance logistics capabilities by further incorporating mobile technologies

Continue to Strengthen and Develop Talent

- · Recruit and develop leaders skilled in HOM tools to drive breakthrough thinking
- · Develop next-generation sales leaders to drive performance and strengthen relationships
- · Expand digital marketing expertise and further develop strategic relationships



COVID-19 Preparedness and Response: Acting Compassionately and Decisively

HILLENBRAND

 Established COVID-19 Task Force and implemented a governance structure with a frequent cadence of reviews at operating company, enterprise, and Board levels Work from home for non-essential onsite employees Physical distancing procedures for employees who need to be onsite Reinforced protocol around feeling ill Documented response plan and protocols to help protect the safety of all associates Hand-washing and hygiene practices across all sites Additional personal protective equipment 	 All major global production locations open and operating at or near normal production levels and deemed essential In close contact with suppliers to manage the supply chain and working with key suppliers on contingency plans Leveraging global manufacturing and flex ible supply chains to move production to different regions as needed
---	--


COVID-19 Business Response: Business Continuity

Hillenbrand

Hillenbrand businesses deemed essential

- Office workers: Majority of functions working from home, including sales teams who are continuing to complete sales
- Manufacturing plants: Operational since they serve critical needs of customers in health and safety, food and agriculture, and energy. Management is maintaining contact with local government authorities to stay open to provide for critical needs
 - India Some facilities in India are closed or operating with a small crew due to Indian government regulations on COVID-19 (less than 5% of HI Revenue)
 - China Facilities were closed for part of Q2. Due to global footprint, business was able to shift much of the work to other locations. China facility is now fully operational, working overtime to complete work, and receiving strong order flow
- Supply Chain: Majority of suppliers continue to perform since they serve critical industries. Some suppliers are delivering later than anticipated due to partial shutdowns, but no significant impact to the business as of now


Significant Production Site Capacity Status



Major manufacturing facilities are operational

¹ Capacity estimates do not include intentional capacity reductions (ex. reductions in workforce due to lower demand).² Number of employees represents the total for that location. Sites with 150 or less employees are not shown.

Proactive Expense and Cash Management



Flexibility To Adjust Upward / Downward Based on the Economic Situation


COVID-19 Response: Liquidity

- Defensive position taken at March 31 to hold ~\$375M+ of cash to address business continuity risks presented by COVID-19 (e.g. primarily broad geographic shutdowns).
- We concluded that the forecast uncertainty brought about by COVID-19 required additional steps to protect and enhance liquidity. Financing amendments to provide additional, temporary flexibility under the covenants were successfully completed on May 19.
- The financing amendments were developed to provide us added flexibility without creating excessive credit risk.
 - Provide reasonable flexibility for economic uncertainty.
 - Enable focus on optimizing the business through the impending recession and obtain additional flexibility for further cost actions, depending on extent of COVID-19 recessionary impact.
 - Re-establish a path back to the long-term capital structure targets.
- With the completion of the financing amendments, we have since resumed normal treasury operations (paid down the revolver with excess cash) as risk has lowered.





FINANCIAL POLICY & PERFORMANCE




¹These represent long term targets or considerations. There can be no guarantee that we will achieve any target or consideration on a specific timeframe or at all.² including pension liabilities.³ As of quarter ended December 31, 2019.

Financial Policy

	The Milacron acquisition resulted in a temporary deviation from well-established financial policies to complete a strategically compelling acquisition; COVID-19 recessionary impact expected to extend timeline to return back to target leverage range (gross debt / EBITDA of 1.6x – 2.8x) ¹
	Capital deployment priority is to de-lever post close
Near-term	Short-dated, pre-payable debt in the capital structure is intended to facilitate de-levering
focus	Atthough COVID-19 triggered our migration to sub-investment grade, we have publicly committed to de- levering
	Focus on successfully integrating Milacron and delivering on near-term financial targets/synergies
	Curtailment of M&A and share repurchases until leverage metrics return to targeted levels
	Dividend reduction/suspension would be considered if more challenging conditions develop
Long-term	Manage leverage back to within established target levels
financial	Continue to transform and optimize portfolio to minimize volatility and create value
policy	Maintain balance sheet flexibility to transact on strategic M&A


These represent long term targets or considerations. There can be no guarantee that we will achieve any target or consideration on a specific timeframe or at all.



HILLENBRAND

Successful Track Record of Delevering Post-Transaction


Combined 3-Year Financial Performance



Together Hillenbrand and Milacron to Gain Significant Size and Scale

¹ FY 17 and FY 18 include PEG and Batewilleresults for the 12 months ended/93017 and 93018, respectively, and Miacron results for the 12 months ended 12/31/17 and 12/31/18, respectively. FY19 includes PEG, Batewille and Miacron results for the 12 months ended 93017 and 93018. As a result, the Miacron results for the fourth quarter of 2018 are effected in both the 2018 and 2018 areas (see a constraint). For Forma Adjusted EBITDA and Adjusted EBITDA Margin are Non-GAAP measures. See Appendix for reconditation.⁻ Miacron results exclude Cambool and Biow Moding boxes es within themes odd in Marcin 2020 and 343 2020 reported in cited Marcin and Hilleforman Corporate explanes.


10-Year Cash Performance Overview



Working Capital Focus Driving FCF Generation and Fueling Investment for Future Growth

¹ Free Cash Flow and Free Cash Flow Conversion are non-GAAP measures. See appendix for GAAP reconciliation.² FY 18 FCF Convension is adjusted for impairment. See appendix for GAAP reconciliation.³ Based on company calculation of PWC/ Annualized quarter Revenue. ⁴ 2015 impacted by working capital timing

Consolidated Performance – Q2 FY 2020¹ (SM)



¹All financial metrics, except for openating cash flow, exclude the diverted Cimocol and Blow Molding Businesses, ²See appendix for discussion of calculation of backlog, ³Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures. See appendix for GAAP reconciliation. INVESTOR PRESENTATION | 40

Portfolio Characteristics & Implications of COVID-19

Business		% of Revenue ¹	Near-term Recessionary Downside Risk	Recent Order Trend (April 2020)	Business Characteristics
	Long-cycle		•	-	 Strong backlog, healthy orders pipeline and good cash profile
Equipment and Systems	Mid-cycle	~50%	•	*	 Exposure to auto, which was experiencing softening demand pre-COVID Contending with India closure and customer disruptions due to COVID-19 pandemic
	Short-cycle			-	 Exposure to auto, which was experiencing softening demand pre-COVID Opportunity in medical, packaging and consumer products
Aftermarket		~25%	•	*	Resilient, quick recoveryHigher margin businessPressure from low machine utilization
Batesville		~20%	•	-	 Non-cyclical, recession resistant Track record of productivity and lean Stable cash flow

1 Q2 FY20; excludes 4% of revenue from Cimcod


Hillenbrand

Well-Positioned for Continued Cash Generation

Downturn/Recession **Timing and Magnitude of** Scenario **Downturns Affect Businesses Differently** Enters cycle quickly; Backlog includes significant Rebounds quickly number of large, long-dated projects Enters cycle slowly; · Small to medium equipment exits slowly enter / exit cycles more EBITDA Large Systems (Long-Cycle) quickly Aftermarket parts and Provides relatively service move in / out of stable trend cycles rapidly Aftermarket · Milacron's businesses track Relatively immune to differently Batesville cyclical swings

Backlog and Increased Aftermarket Sales Expected to Support More Stable Cash Generation Stability of Batesville Cash Flow





CAPITALIZATION OVERVIEW

Capital Position and Liquidity

\$M)	As of 3/31/20	% of Total Cap.	PF Adj. EBITDA (ex. Cimcool
Cash & Cash Equivalents	\$374	nor rour oup.	TT Auj. EDITER (CA. Onicoo)
\$900M Senior Unsecured Revolver due Aug. 2024	538	14.2%	1.3x
3-Year Senior Unsecured Term Loan A due Nov. 2022	222	5.8%	0.5x
5-Year Senior Unsecured Term Loan A due Nov. 2024	492	13.0%	1.2x
4.60% Series A Notes due Dec. 2024	100	2.6%	0.2x
5.50% Senior Unsecured Notes due July 2020	150	3.9%	0.4x
4.50% Senior Unsecured Notes due Sept. 2026	370	9.8%	0.9x
Other Debt	2	-	
Total Debt ¹	\$1,873	49.3%	4.4x
Total Net Debt	\$1,499	39.5%	3.5x
Market Value of Equity (As of 5/29/20)	1,923	50.7%	2.04
Total Capitalization	\$3,797		8.9x
Enterprise Value	\$3,423		8.0x
LTM 3/31/20 Pro Forma Adj. EBITDA (ex. Cimcool) ²	\$427		
Cash on B/S	374		
Revolver Availability ³	354		
Total Liquidity	\$728		

Debt Maturity Profile as of March 31, 20204

Drawn Revo	olver ⁵ 3-year Te	m Loan A-26	■Bonds due 2026	5-year Term Loan /	A-1 7 Series A Notes	Bonds due 2020
				\$5	37.6	
0 811.3		\$198.3		\$3	62.5	\$375.0
\$150.0	\$12.7		\$37.5	\$40.6 \$1	00.0	

Note: Calindary year end ¹ Amounts shown are net of deblissuane costs.² Pro Forma Ag, EBITDA is a non-GAAP measure. See Appendix for reconciliation.³ Pro forma for recertly completed amendment; defined as lesser of undrawn revolver (less outstanding LCs of c. SBM) and availability under the existing 4.7 shown are net of deblissuane costs.² Pro Forma Ag, EBITDA is a defined into Credit Agreement (Cash Netting defined as 100% of unrestricted and unencumbered cash and cash equivalents outside of the United States, not to exceed \$175ML.⁴ Debtalances are reflected gross rather than net of deferred financing fees.⁶ Total revolver size of \$000M (\$354M of undrawn availability after giving effect tooutstanding letters of credit, ³Assumes amortization of \$0% / 5.0% / 7.5% / 10.0% / builet.⁷ INVESTOR PRESENTATION | 44



Key Takeaways

01	02	03	04	05	06
Significant Strides	Market Leadership	The Hillenbrand	Focused on Building	Strong Free Cash	Passionate
Transforming	Driven by Highly-	Operating Model	Platforms to	Flow With Focus	Leadership Team
Hillenbrand into a	Engineered	(HOM) is a	Develop Scale and	on Paying Down	Driving
Global Diversified	Products with Core	Competitive	Enhance	Debt Post-Milacron	Transformation with
Industrial	Technologies	Differentiator;	Leadership	Acquisition;	Runway for
Company	Differentiated by	Historically Focused	Positions to Drive	Temporarily	Significant
	Applications	on Margin	Profitable Growth;	Lowering Priority of	Shareholder Value
	Expertise	Expansion and Now	Integrating Milacron	M&A and Share	Creation
		Adding Tools to	is a Key Priority	Repurchases	
		Drive Profitable			
		Growth			



While we report financial results in accordance with United. States generally accepted accounting principles (GAAP), we also provide certain non-GAAP operating performance measures. These non-GAAP measures are referred to as "adjusted" measures and exclude the following items:

- · business acquisition, disposition, and integration costs;
- · restructuring and restructuring related charges;
- · asset impairment charges:
- inventory step-up charges;
- backlog amortization;
- · debt financing activities related to the acquisition of Mlacron
- · net loss on divestiture of Cirrcool;
- · the related income tax impact for all of these items; and

 non-recurring tax benefits and expenses related to the interaction of certain provisions of the Tax Cuts and Jobs Act of 2017 (the "Tax Act") and certain tax items related to the acquisition of Milacron and divestiture of Cimcool. Non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP

One important non-GAAP measure that we use is adjusted earnings before interest, income tax, depreciation, and amortization ("adjusted EBITDA"). A part of our strategy is to pursue acquisitions that strengthen or establish leadership positions in key markets. Given that strategy, it is a natural consequence to incur releated expenses, such as amortization from acquired intangible assets and additional interest expense from debt-funded acquisitions. Accordingly, we use adjusted EBITDA mong other measures, to montor our business performance. Adjusted EBITDA is not a recognized term under U.S. GAAP and therefore does not purport to be an alternative to net (loss) income. Further, Hilenbrand's measure of adjusted EBITDA, may not be comparable to similarly titled measures of other companies.


Free cash flow (FCP) is defined as cash flow from operations less capital expenditures. Hilenbrand uses a related term, free cash flow to net income conversion rate, to refer to free cash flow divided by GAAP net income. Hilenbrand considers FCP and free cash flow to net income conversion rate important indicators of Hilebrand's liquidity, as well as its ability to fund future growth and to provide a return to shareholders. FCP does not include deductions for debt service (repayments of principal), other terms: on Hilebrand's common stock, repurchases of Hilebrand's Lossifiers on Hilebrand's liquidity.

Another important non-GAAP measure used is backlog. Backlog is not a term recognized under GAAP, however, it is a common measurement used in industries with extended lead times for order fulfilment (long-term contracts), like those in which our Process Equipment Group and Miacron businesses compete. Backlog represents the amount of consolidated revenue that we expect to realize on contracts awarded related to the Process Equipment Group and Miacron businesses compete. Backlog represents the amount of consolidated revenue that we expect to realize on contracts awarded related to the Process Equipment Group and Miacron businesses, compete backlog, represents the automative abustiaries is in cliculated. Backlog represents the amount of consolidated revenue throw the process Equipment, as well as replacement parts, components, and service. Given that there is no GAAP financial measure comparable to backlog, a quantitative reconciliation is not provided.

We use this non-GAAP information internally to make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of our ongoing operating results. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by these types of items. The Company believes this information provides a higher degree of transparency.

Segment Performance: Process Equipment Group (\$M)





· Record backlog of \$982M, up 2% over prior year and up 9% sequentially

Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures. See appendix for GAAP recondition.

Segment Performance: Milacron (\$M)



Performance Highlights

- Milacron pro forma revenue of \$173M decreased 21% compared to the prior year due to continued softness for injection molding equipment and hot runner systems in certain end markets, including automotive; demand pressure was further exacerbated by the impact of COVID-19 $\,$
- Pro Forma Adj. EBITDA margin of 15.6% decreased 330 basis points vs. the prior year primarily due to lower volume
- Backlog of \$187M decreased 17% year over year due to lower injection molding and extrusion equipment orders; however, backlog grew 28% sequentially for both hot runner systems and injection molding equipment •
- . Injection molding and extrusion equipment saw a sequential increase in orders in the fiscal second quarter, but that momentum slowed in March and continued to decline in April
- Order rates for hot runner systems, however, improved in March and April versus January and February, as government shutdowns in China were relaxed or lifted, and demand for medical and pharmaceutical projects increased due to the COVID-19 pandemic
 - · Continued focus on discretionary cost controls

1 All financial metrics exclude the diverted Cimcool and Blow Molding businesses.² Pro Forma Adjusted EBITDA and pro forma adjusted EBITDA margin are non-GAAP measures. See appendix for GAAP reconciliation.

Segment Performance: Batesville (\$M)



- · Revenue of \$139M increased 1% over the prior year; the increase in revenue was primarily driven by higher volume, despite an estimated decrease in North American burials due to an increased rate at which families opted for cremation
- Adj. EBITDA margin of 23.1% improved by 20 bps over the prior year driven primarily by productivity initiatives and higher volume, partially offset by inflation in wages and benefits

· Batesville experienced increased demand late in the fiscal second quarter, which continued through April, in certain markets reporting increased mortality associated with the COVID-19 pandemic

· Continued focus on discretionary cost controls


Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures. See appendix for GAAP reconditation.

INVESTOR PRESENTATION 151


Business Update

Large Installed Base Provides Long Tail for Revenue Generation






Individual Components to Integrated Systems in Plastics



Equipment &	Compounding &	Materials
Components	Extrusion Systems	Handling
 Feeding equipment and components for large and small systems Feeders Highly-engineered valves Pneumatic conveying subsystems 	 Highly-engineered conversion systems used in high volume polyolefin production (polyethylene and polypropylene) Smaller conversion systems for engineered plastics, PVC, and chemicals 	 Large engineered pneumatic material handling systems mainly for the polyolefin industry Turnkey Solutions – Coperion engineers all key equipment and processes for a turnkey plant

Strengthens Position Across Plastics Value Chain and Enhances Growth Opportunity

HILLENBRAND



Better Positioned to Serve Customers and Cross-Sell Products

Reconciliation of Pro Forma Adjusted EBITDA to Consolidated Net (Loss) Income

(in millions)		Pro F Six Months En 2020	orma ided Ma	urch 31, 2019	Ye	o Forma ar Ended tember 30, 2019	Pro Forma Last Twelve Months Ended March 31, 2020		
Pro forma consolidated net (loss) income	\$	(26.1)	\$	68.0	\$	137.4	\$	43.3	
Interest income		(2.3)		(2.1)		(4.1)		(4.3)	
Interest expense		41.9		48.6		96.8		90.1	
Income tax expense		24.1		26.1		62.7		60.7	
Depreciation and amortization		64.8		66.4		133.1		131.5	
Pro forma EBITDA	100	102.4	80	207.0		425.9		321.3	
Impairment charges (1)		82.5						82.5	
Business acquisition, disposition, and integration costs (2)		4.7		1.3		3.8		7.2	
Restructuring and restructuring-related charges (3)		4.5		15.0		30.2		19.7	
Inventory step-up (4)				0.2		0.2		-	
Net loss on divestiture (5)		3.0				-		3.0	
Other (6)		9.7		4.3		11.1		16.5	
Pro forma adjusted EBITDA		206.8		227.8		471.2		450.2	
Less: Cimcool adjusted EBITDA		(10.2)		(13.6)		(26.8)		(23.4)	
Pro forma adjusted EBITDA, excluding Cimcool	\$	196.6	\$	214.2	\$	444.4	\$	426.8	
Pro forma adjusted EBITDA by segment:									
Process Equipment Group	\$	109.0	\$	101.7	\$	223.3	\$	230.6	
Milacron		59.2		89.5		182.0		151.7	
Batesville		55.0		58.3		114.2		110.9	
Corporate		(26.6)		(35.3)		(75.1)		(66.4)	
	\$	196.6	\$	214.2	\$	444.4	\$	426.8	

(1)

During the six months ended March 31, 2020, Hilestbrand recorded impairment charges to goodwill and certain identifiable intengible assets within both the Process Equipment Oroup and Milecton reportable segments. Business acquiation, disposition, and integration costs were primarly related to professional fees and other transaction costs in connection with the divestitures of the Crincool business in March 2020 and thebiowmolding business in July 2019, along with the acquisition and integration of Busnaky Machine and Mill Equipment Ltd. ("BMAM") in November 2018. Restructuring and restructuring-educid charges impairment and were and other transaction costs as a result of eliminated positions. Restructuring and restructuring-educid charges impairment of inventories acquired in connection with the acquisition of BuSM in November 2018. Restructuring and restructuring-educid charges impairment of inventories acquired in connection with the acquisition of BuSM in November 2018. Restructuring accurate a context accuration of the far value adjustment of inventories acquired in connection of BuSM in November 2018. Cher costs primarly included the write-down of inventory associated with the COVIID-19pan demic. (2)

(3) (4) (5) (6)

Reconciliation of Pro Forma Revenue to Reported Revenue

Consolidated Revenue Reconciliation

	A	ctual	Pro Forma Pro Forma					P	ro Forma		Pro Forma						
	Three M	onths Ended	Three Months Ended		Six	Months En	ded	March 31,	Ye	ar Ended		Years Ended	Dece	mber 31,			
(in millions)	Marcl	h 31, 2020	March 31, 2019			2020		2019	September 30, 2019			2018		2017			
Consolidated net revenue	\$	648.9	\$	713.3	\$	1,331.5	\$	1,413.1	\$	2,867.2	\$	2,934.8	\$	2,729.7			
Less: Cimcool net revenue		(26.0)		(29.3)		(53.3)		(60.4)		(119.9)		(129.3)		(121.2)			
Consolidated net revenue, excluding Cimcool	\$	622.9	\$	684.0	\$	1,278.2	\$	1,352.7	\$	2,747.3	\$	2,805.5	\$	2,608.5			

Milacron Revenue Reconciliation

	Three M	onths Ended	Three Months Ended			Months En	ded	March 31,	Yea	ar Ended	1	Years Ended December 31					
(in millions)	Marci	1 31, 2020	March 31, 2019		2020			2019	September 30, 2019			2018		2017			
Milacron net revenue	\$	199.0	\$	248.7	\$	448.0	\$	538.2	\$	1,059.9	\$	1,164.7	\$	1,139.5			
Less: Cimcool net revenue		(26.0)		(29.3)		(53.3)		(60.4)		(119.9)		(129.3)		(121.2)			
Milacron net revenue, excluding Cimcool	\$	173.0	\$	219.4	\$	394.7	\$	477.8	\$	940.0	\$	1,035.4	\$	1,018.3			

Reconciliation of Hillenbrand Adjusted EBITDA to Consolidated Net (Loss) Income

	 Three Months E	nded I	March 31,	Years Ended September 30,							
(in millions)	2020		2019		2018		2017				
Consolidated net (loss) income	\$ (72.2)	\$	39.5	\$	81.2	\$	128.4				
Interest income	(0.6)		(0.2)		(1.4)		(0.9)				
Interest expense	20.9		5.4		23.3		25.2				
Income tax expense	1.8		13.8		65.3		59.9				
Depreciation and amortization	38.6		15.1		56.5		56.6				
EBITDA	(11.5)	-	73.6	-	224.9	-	269.2				
Impairment charges	82.5		-		63.4		-				
Business acquisition, disposition, and integration costs	8.0		0.5		3.5		1.1				
Restructuring and restructuring-related charges	0.7		0.7		2.5		10.7				
Inventory step-up	27.5		0.1		-		-				
Net loss on divestiture	3.0		-		-		-				
Other	0.4		-		-		-				
Adjusted EBITDA	 110.6		74.9		294.3		281.0				
Less: Cimcool adjusted EBITDA	(4.9)		-		-		-				
Adjusted EBITDA, excluding Cimcool	\$ 105.7	\$	74.9	\$	294.3	\$	281.0				
Adjusted EBITDA by segment:											
Process Equipment Group	\$ 57.5	\$	55.5	S	215.8	\$	177.7				
Milacron	27.0		-				-				
Batesville	32.0		31.6		120.8		141.9				
Corporate	(10.8)		(12.2)		(42.3)		(38.6)				
	\$ 105.7	\$	74.9	\$	294.3	\$	281.0				

	onths Ended rch 31,	 Years Ended December 31,						
(in millions)	2019	 2018		2017				
Consolidated net (loss) income	\$ (0.8)	\$ 41.5	\$	1.1				
Loss from discontinued operations (net of income taxes)	10.0	5.1		6.7				
Interest expense	9.5	42.9		44.5				
Income tax expense	7.0	18.5		14.9				
Depreciation and amortization	11.9	52.1		54.3				
Currency effect on intercompany advances	(1.6)	3.1		(6.7				
Long-term equity awards	3.2	10.1		9.4				
Debt costs	-	1.2		27.1				
Business acquisition, disposition and integration costs	0.7	4.0		6.0				
Restructuring and restructuring-related charges	1.1	35.7		51.3				
Other		5.4		12.5				
Adjusted EBITDA (as reported by Milacron)	41.0	 219.6		221.1				
Less: Adjustments to conform with Hillenbrand:								
Currency effect on intercompany advances	1.6	(3.1)		6.7				
Long-term equity awards	(3.2)	(10.1)		(9.4				
Adjusted EBITDA (conformed to Hillenbrand)	39.4	206.4		218.4				
Less: Cimcool adjusted EBITDA	(6.4)	 (29.3)		(26.9				
Adjusted EBITDA, excluding Cimcool	\$ 33.0	\$ 177.1	\$	191.5				
Adjusted EBITDA by segment								
Milacron (1)	\$ 41.5	\$ 212.4	\$	225.2				
Corporate	(8.5)	(35.3)		(33.7				
	\$ 33.0	\$ 177.1	\$	191.5				

(1) Includes Milacron's segment EBITDA as if Milacron was a segment of Hilenbrand for the periods presented above.

(\$ in millions)								Y	ears En	de	d Septe	mb	er 30,				
		2019		2018	2017		2016		2015		2014		2013	2012	2011		2010
Operating Activities																	
Consolidated Net Income (A)	\$	126.2	\$	81.2	\$ 128.4	S	116.8	\$	113.2	\$	111.2	\$	65.4	\$ 104.8	\$ 106.1	\$	92.3
Depreciation and Amortization		58.5		56.5	56.6		60.4		54.3		58.4		89.4	40.4	36.1		28.2
Impairment Charge (D)		-		63.4	-		-		-		-		-	-	-		-
Change in Working Capital		(28.4)		4.6	33.3		51.2		(86.8)		22.6		(12.3)	(19.8)	(16.4)		16.9
Pension Settlement		-		-	-		-		17.7		-		-	-	-		-
Other, Net	S	22.6	s	42.6	\$ 27.9	\$	9.8	\$	6.6	\$	(12.6)	\$	(15.3)	\$ 12.8	\$ 63.7	s	(19.2)
Net Cash Provided by Operating Activities (B)		178.9		248.3	246.2		238.2		105.0		179.6		127.2	138.2	189.5		118.2
Capital Expenditures (C)		(25.5)		(27.0)	(22.0)		(21.2)		(31.0)		(23.6)		(29.9)	(20.9)	(21.9)		(16.3)
Acquisition of Businesses, Net of Cash Acquired		(25.9)		-	-		(235.4)		-		-		(415.7)	(4.4)	(240.9)		(371.5)
Debt Activity		272.2		(174.1)	(147.2)		83.8		(26.2)		(104.1)		385.6	(162.3)	28.1		334.2
Dividends		(52.6)		(52.1)	(51.9)		(51.1)		(50.4)		(49.7)		(48.7)	(47.6)	(46.9)		(46.2)
Other		(4.2)		(5.1)	(11.1)		(10.6)		(7.1)		13.1		4.0	1.7	109.2		44.8
Net Change in Cash	S	342.9	S	(10.0)	\$ 14.0	\$	3.7	\$	(9.7)	\$	15.3	\$	22.5	\$ (95.3)	\$ 17.1	\$	63.2
Free Cash Flow (B-C)	\$	153.4	\$	221.3	\$ 224.2	\$	217.0	\$	74.0	\$	156.0	\$	97.3	\$ 117.3	\$ 167.6	\$	101.9
Free Cash Flow Conversion (FCF/(A+D))		122%		154%	175%		186%		65%		140%		149%	112%	158%		110%